2022 ANZUP ASM
2022 ANZUP ASM
2022 ANZUP ASM
ASM CONVENOR MESSAGE
On behalf of the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group convening committee, I was honoured to convene the 11th Annual Scientific Meeting (ASM) from 10 – 12 July 2022 at the Adelaide Convention Centre. This year’s ASM theme ‘No Longer on Mute: Patients, Carers and Our Research Community’ provided a platform to discuss the need for a voice for many groups – the patient, carers, vulnerable communities, other disciplines, and the research community – about clinical trials. It was thrilling to be able to finally come together face-to-face and network, re-ignite old friendships, debate, discuss and appreciate the multidisciplinary group of healthcare professionals in attendance.
Throughout the 3-day meeting, delegates had the opportunity to interact with and learn from four international experts and numerous national leaders in the research, diagnosis, treatment and management of GU cancers, always with the collegial spirit that defines ANZUP.
The ASM was truly multidisciplinary – there were sessions to suit everyone working in GU cancers. The program included a highly successful new Clinical Trials Research Symposium, the popular MDT Masterclass, the Translational and Supportive Care breakfast sessions, the always well-attended Nurses Symposium, the extremely topical and important plenary session, ‘Raising your voice for equity in cancer care’, ANZUP trial updates, and of course the much-anticipated Crossfire Debates and poster presentations, as well as many more very informative sessions.
We were fortunate to have more than 80 speakers, panelists, session chairs and poster presenters take part in more than 20 different sessions throughout the three days. This is a great reflection on the diversity and breadth of ANZUP’s now 2,050-strong membership.
In addition, our international faculty were a highly engaged group, providing a global perspective on many of the significant issues facing GU cancer experts. Over the three days, the quality and impact of our international faculty cannot be overstated, with Himisha Beltran, Noel Clarke, Christopher Sweeney, Andrew Loblaw, Bertrand Tombal, Samra Turajlic, and Susanne Vahr Lauridsen playing a significant part in all facets of the meeting both in person and virtually.
Other highlights included a Q&A evening symposium hosted by Ben Tran who tackled the topic of “Survivorship Unmuted.” With the panel of GU cancer survivors, they addressed what survivorship means and what life after treatment looks like.
The annual free Community Engagement Forum featured presentations and panel discussions covering quality of life, treatment choices, survivorship, impacts on intimacy and the cost of cancer care. This session gave the public the opportunity to engage with an experienced team of healthcare professionals and patient advocates while learning about ANZUP and our clinical trials research program.
Also new to this year’s ASM was the inaugural ANZUP Outstanding Leadership Award. This award, and standing ovation, was truly deserved by Guy Toner. This award recognised his immense contribution to both ANZUP and GU cancer research. Guy was part of ANZUP’s inception and provided unwavering guidance, advice, and knowledge throughout his years as the Deputy Chair of ANZUP and trial investigator of various studies.
This year we again had fabulous Twitter engagement of close to 1.8 million #ANZUP22 impressions and over 800 tweets. Attendance was impressive with close to 400 delegates – all testament to the high quality, academic, educational, entertaining ASM for which ANZUP has become renowned.
Thank you to every speaker, sponsor, chair, delegate, participant, committee member and organiser for your contribution.